Choline and Blood Sugar
Choline has a real connection to blood sugar, and it is the most two-sided entry in this section. Too little damages the liver in a way that drives insulin resistance. Too much feeds a gut-bacterial pathway associated with higher diabetes risk. It is one of the few nutrients here where "more" is not the direction of the answer.
Evidence tier 2, and non-linear. The target is sufficiency, not maximisation.
Table of Contents
A Note on the B-Number
Choline is frequently sold and described as vitamin B4, and it is often confused with vitamin B8. The historical record is specific and worth stating because the two are sold together:
- Choline carried the designations B4 and Bp.
- Inositol was B8.
Neither is a vitamin under the modern definition — the body synthesises both, choline in the liver via phosphatidylethanolamine N-methyltransferase and inositol from glucose — which is why both were retired from the B-series. Choline is now classified as an essential nutrient with a formal Adequate Intake, which is a different and stronger status than "vitamin-like." See former vitamins for the full cross-reference, and inositol for its partner in most combination products.
Too Little: The Liver Route
Choline's connection to blood sugar runs through the liver, and the mechanism is structural rather than hormonal.
Exporting fat out of the liver requires very-low-density lipoprotein, and assembling VLDL requires phosphatidylcholine — which requires choline. Without enough, triglyceride accumulates in hepatocytes because it cannot be packaged and shipped. The result is hepatic steatosis, and hepatic steatosis is one of the tightest correlates of insulin resistance there is: a fatty liver responds poorly to insulin's instruction to stop producing glucose, so fasting glucose drifts up.
This is the same ectopic-lipid mechanism described on the insulin resistance page, arrived at from a nutritional direction. It is a genuine, mechanistically coherent route from a choline shortfall to a glucose problem.
Too Much: The TMAO Route
The other direction is less intuitive and is why this page does not end with "supplement choline."
Gut bacteria metabolise choline (and carnitine) to trimethylamine, which the liver oxidises to trimethylamine N-oxide. Mohammadi and colleagues' 2025 systematic review and meta-analysis in Obesity Reviews examined gut microbiota-derived TMAO and the risk of diabetes; TMAO has been repeatedly associated with adverse cardiometabolic outcomes.
There is a second signal in the same direction. Saulnier and colleagues' 2025 prospective study in Diabetes & Metabolism, spanning Asian and European cohorts, found that among methylamine metabolites choline was the one consistently associated with progression of diabetic kidney disease in both populations.
Two caveats keep this honest. Association is not causation, and TMAO may be a marker of a gut microbiome that produces it rather than the agent of harm. And TMAO production depends heavily on which bacteria you have, which is why identical choline intakes produce very different TMAO levels in different people.
What the Human Evidence Actually Says
Vallianou and colleagues' 2024 review in Current Nutrition Reports is the balanced summary of this literature, and its framing — an interplay between dietary choline and cardiometabolic disorders — is the accurate one. Wu and colleagues examined the association of dietary choline and betaine intake with diabetes risk in a prospective cohort from the China Health and Nutrition Survey, published in Food & Function in 2026.
What no one has is a randomised trial showing that choline supplementation improves glycemic control in people who are not deficient. The evidence base is observational and mechanistic, which supports avoiding a shortfall and does not support supplementing beyond it.
Betaine deserves a mention because it recurs alongside choline in these papers: choline is oxidised to betaine, which donates a methyl group in homocysteine metabolism. Adequate betaine intake spares choline for its phosphatidylcholine role, which is one reason the two are studied as a pair.
Getting Enough Without Overshooting
The Adequate Intake is 550 mg/day for men and 425 mg/day for women (450 mg in pregnancy, 550 mg when breastfeeding). Most people fall short of it, and the gap is largest in diets that exclude eggs and organ meats.
Food is the sensible route, and unlike several entries in this section, food can genuinely reach the target:
- Eggs — the single most practical source; roughly 150 mg per large egg, nearly all of it in the yolk.
- Liver — the densest source by a wide margin.
- Meat, fish and poultry — moderate and reliable.
- Soybeans, cruciferous vegetables, and legumes — the main plant contributors, less concentrated.
Two groups are most at risk of a genuine shortfall: people on strict plant-based diets, and post-menopausal women, whose endogenous synthesis falls as oestrogen declines. Those are the people for whom the liver mechanism above is a live concern rather than a theoretical one.
Choline + Inositol Products
Choline and inositol are commonly sold as a single combination product, usually in equal amounts, and the pairing is historical rather than evidential: both were once B-vitamins, both are lipotropic (they participate in fat handling in the liver), so they were bundled and have stayed bundled.
There is no trial showing the combination outperforms either alone for blood sugar. If you want either compound for a specific reason, note that the reasons are different:
- Inositol has genuine trial support — in PCOS and, more strongly, in gestational diabetes prevention. Effective doses are 2–4 g/day.
- Choline has an intake target to meet, not a therapeutic dose to take, and combination products typically supply far less than the Adequate Intake anyway.
A typical choline-and-inositol capsule therefore tends to under-dose both: too little choline to close a dietary gap, and too little inositol to match any trial protocol.
Cautions
- It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
- More is not better here, which is unusual on this page. High supplemental choline raises TMAO, and the tolerable upper intake level is 3.5 g/day — above which fishy body odour, sweating, low blood pressure and gastrointestinal effects appear.
- Fishy body odour is the classic sign of excess, from trimethylamine, and is severe in the genetic condition trimethylaminuria.
- Established kidney disease is a reason for caution given the diabetic kidney disease association above; discuss supplementation rather than assuming it is harmless.
- Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Vallianou N, et al. The Interplay Between Dietary Choline and Cardiometabolic Disorders: A Review of Current Evidence. Current Nutrition Reports, 2024;13(2):152–165. The balanced summary of both directions.
- Wu S, Chen P, Sui Y, et al. Association of dietary choline and betaine intake with diabetes risk: a prospective cohort study from the China Health and Nutrition Survey. Food & Function, 2026;17(6):2871–2883.
- Mohammadi, et al. Gut Microbiota-Derived Trimethylamine N-Oxide and the Risk of Diabetes: An Updated Systematic Review and Meta-Analysis. Obesity Reviews, 2025;26(11):e13963.
- Saulnier PJ, et al. Methylamine metabolites and progression to kidney failure in type 2 diabetes: An Asian and European prospective study. Diabetes & Metabolism, 2025;51(4):101658. Choline was the metabolite consistently associated with progression in both cohorts.